Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension

NCT02203916 ↗

Phase 3 Completed 328 enrolled Takeda

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare the antihypertensive effect of azilsartan medoxomil versus placebo in Korean adults with essential hypertension.

Timeline

Start: 2014-07
Primary completion: 2016-01
Completion: 2016-02

Outcome

Met primary endpoint

registry Placebo vs Azilsartan Medoxomil 40 mg; p <0.001; LS Mean Difference -13.317 (95% CI -18.138 to -8.497) NCT02203916 ↗

registry Placebo vs Azilsartan Medoxomil 80 mg; p <0.001; LS Mean Difference -14.955 (95% CI -19.770 to -10.141) NCT02203916 ↗

Publications

Juhasz A, Wu J, Hisada M, Tsukada T, Jeong MH. Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension. Clin Hypertens. 2018 Feb 7;24:2. doi: 10.1186/s40885-018-0086-4. eCollection 2018.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Azilsartan medoxomil	Other / unclassified	40 mg	Oral
Subject	Azilsartan medoxomil	Other / unclassified	80 mg	Oral